Evidence map›Paper›PMID 32564128›Full record

Trial reportCancer chemotherapy and pharmacology2020

A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703).

Shin-Ichi Fukumoto, Satoshi Oizumi, Masao Harada, Noriaki Sukoh, Kosuke Nakano, Satoshi Fuke, Jun Sakakibara-Konishi, Kei Takamura, Kenichiro Ito, Yuka Fujita and 9 more

Abstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Cancer chemotherapy and pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Nanomedicine Innovations for Lung Cancer Diagnosis and Therapy.ACS applied materials & interfaces · 2025
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 8 institutions in 1 country.

Shin-Ichi FukumotoDepartment of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, 2-3-54 Kikusui 4-jo, Shiroishi-ku, Sapporo, 003-0804, Japan. s1004fuku@gmail.com.ORCID http://orcid.org/0000-0001-6386-7451
Satoshi OizumiFirst Department of Medicine, Hokkaido University Hospital, Sapporo, Japan.
Masao HaradaDepartment of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, 2-3-54 Kikusui 4-jo, Shiroishi-ku, Sapporo, 003-0804, Japan.
Noriaki SukohDepartment of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, 2-3-54 Kikusui 4-jo, Shiroishi-ku, Sapporo, 003-0804, Japan.
Kosuke NakanoDepartment of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, 2-3-54 Kikusui 4-jo, Shiroishi-ku, Sapporo, 003-0804, Japan.
Satoshi FukeDepartment of Medical Oncology, KKR Sapporo Medical Center, Sapporo, Japan.
Jun Sakakibara-KonishiFirst Department of Medicine, Hokkaido University Hospital, Sapporo, Japan.
Kei TakamuraDepartment of Respiratory Medicine, Obihiro-Kosei General Hospital, Obihiro, Japan.
Kenichiro ItoDepartment of Respiratory Medicine, Obihiro-Kosei General Hospital, Obihiro, Japan.
Yuka FujitaDepartment of Respiratory Medicine, National Hospital Organization Asahikawa Medical Center, Asahikawa, Japan.
Yutaka NishigakiDepartment of Respiratory Medicine, National Hospital Organization Asahikawa Medical Center, Asahikawa, Japan.
Toshiyuki HaradaCenter for Respiratory Diseases, JCHO Hokkaido Hospital, Sapporo, Japan.
Kenji AkieDepartment of Respiratory Medicine, Sapporo City General Hospital, Sapporo, Japan.
Ichiro KinoshitaDepartment of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Toraji AmanoDepartment of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Hiroshi IsobeDepartment of Medical Oncology, KKR Sapporo Medical Center, Sapporo, Japan.
Hirotoshi Dosaka-AkitaDepartment of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Masaharu NishimuraFirst Department of Medicine, Hokkaido University Hospital, Sapporo, Japan.
Hokkaido Lung Cancer Clinical Study Group
National Hospital Organization Hokkaido Medical Center · JPHokkaido University Hospital · JPSapporo Medical University · JPAsahikawa Medical University · JPNTT Medical Center · JPObihiro Kosei General Hospital · JPHokkaido hospital · JPSapporo City General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study evaluated the efficacy and safety of platinum plus gemcitabine (P/G) combinations as postoperative adjuvant chemotherapies for non-small cell lung cancer.

methodsPatients with postoperative stage IB-IIIA non-small cell lung cancer were randomly assigned to receive either cisplatin plus gemcitabine (GP arm) or carboplatin plus gemcitabine (GC arm) every 3 weeks for four cycles. The primary endpoint was 2-year disease-free survival (DFS). Secondary endpoints were safety, feasibility, overall survival (OS), and biomarker analyses.

resultsA total of 102 patients were randomized (stage IB, 22%; II, 36%; IIIA, 42%; histology: 74% adenocarcinoma). Of the 51 patients in each arm, 37 (73%) completed 4 cycles. During follow-up (median 5.8 years; range 0.1-9.7 years), estimated DFS and OS rates at 2 years were 59.6% and 86.3% with GP and 68.0% and 86.3% with GC, respectively. No significant difference in DFS was noted between arms (P = 0.163), although 3-, 4-, and 5-year DFS rates were higher with GC. Hematological toxic effects were comparable and non-hematological toxic effects were infrequent. DFS was significantly higher in the excision repair cross-complementation group 1 (ERCC1)-low group than in the ERCC1-high group for the GP arm (P = 0.045).

conclusionBoth P/G combination regimens were feasible and well-tolerated, and thus may represent valid options for postoperative adjuvant treatment of non-small cell lung cancer. Although no significant differences in DFS were evident between regimens, the present data favor the adoption of GC for further evaluation. CLINICAL

trial registrationUMIN-CTR ( https://www.umin.ac.jp/ctr/ ) identifier: UMIN000000913.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarboplatinCarcinoma, Non-Small-Cell LungCisplatinDeoxycytidineDisease-Free SurvivalDNA-Binding ProteinsEndonucleasesFemaleGemcitabineHumansLung NeoplasmsMaleBiomarkers, TumorCarboplatinCisplatinDeoxycytidineDNA-Binding ProteinsEndonucleasesERCC1 protein, humanGemcitabineRibonucleoside Diphosphate ReductaseRRM1 protein, humanAdjuvant chemotherapyGemcitabineNon-small cell lung cancerPlatinum

Identifiers

PMID32564128
OpenAlexW3035873975

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.